News
-
23.06.2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations - -
18.06.2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation
PRESS RELEASES
23-Jun-2009Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations -
18-Jun-2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation
26-May-2009
DiagnoSwiss remporte le "Prix Debiopharm Valais pour les Sciences de la Vie" pour sa technologie de bio-micro-électronique innovante
11-May-2009
Debiopharm and Mepha sign distribution agreement for Pamorelin® LA 1-3- and 6-month formulations - a new treatment for prostate cancer patients in Switzerland -
30-Apr-2009
Clinical Update – Debio 025 in Hepatitis C - Debiopharm starts phase IIb study after record time patient randomisation
|
|